NextCure, Inc.
NXTC
$12.20
$0.241.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.27% | -12.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.08% | -67.22% | |||
| Operating Income | -9.08% | 67.22% | |||
| Income Before Tax | -9.42% | 67.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.42% | 67.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.42% | 67.83% | |||
| EBIT | -9.08% | 67.22% | |||
| EBITDA | -11.65% | 68.45% | |||
| EPS Basic | 26.45% | 71.45% | |||
| Normalized Basic EPS | 26.45% | 71.45% | |||
| EPS Diluted | 26.45% | 71.45% | |||
| Normalized Diluted EPS | 26.45% | 71.45% | |||
| Average Basic Shares Outstanding | 48.77% | 12.69% | |||
| Average Diluted Shares Outstanding | 48.77% | 12.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||